Resumen de Lanadelumab to treat hereditary angioedema.
Lanadelumab is a human monoclonal antibody against plasma kallikrein indicated for prevention of attacksofhereditaryangioedema(HAE).HAEiscaused bySERPING1genemutationsresultingindecreasedor dysfunctional plasma protease C1 inhibitor (C1-INH) leading to a loss of inhibition of plasma kallikrein activity with subsequent cleavage of high-molecular-weight kininogen and release of bradykinin. There is a clear need for a non-plasma-derived, safe, effective and convenient prophylaxis of HAE attacks to reduce patients' daily burden of disease and disability. The percentage of patients who were attack-free for the last 16 weeks of a controlled study was 77% in the group receiving 300 mg lanadelumab every 2 weeks, compared with 3% with placebo. The most common side effects were mild injection-site reactions. Lanadelumab has the potential to change the approach from on-demand treatment to prophylaxis in HAE. Future studies will have to confirm long-term safetyandefficacyofprophylacticlong-terminhibition ofplasmakallikrein.
